RETRACTED: The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis
Authors:
Open Access
- 17 February 2023
- journal article
- retracted article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1095362
Abstract
Introduction: Anlotinib, a novel multi-kinase inhibitor, was found to improve progression-free survival (PFS) in brain metastases.Methods: This paper retrospectively analyzed 26 newly diagnosed or recurrent high-grade gliomas from 2017 to 2022, and the patients received oral anlotinib during concurrent postoperative chemoradiotherapy or after recurrence. Efficacy was evaluated according to the Response Assessment in Neuro-Oncology (RANO) criteria, and the main study endpoints were PFS at 6 months and overall survival (OS) at 1 year.Results: After the follow-up, until May 2022, 13 patients survived and 13 patients died, with a median follow-up time of 25.6 months. The disease control rate (DCR) was 96.2% (25/26), and the overall response rate (ORR) rate was 73.1% (19/26). The median PFS after oral anlotinib was 8.9 months (0.8–15.1), and the PFS at 6 months was 72.5%. The median OS after oral anlotinib was 12 months (1.6–24.4), and the OS at 12 months was 42.6%. Anlotinib-related toxicities were observed in 11 patients, mostly grades 1–2. In the multivariate analysis, patients with Karnofsky Performance Scale (KPS) above 80 had a highermedian PFS of 9.9months (p = 0.02), and their sex, age, IDH mutation, MGMTmethylation, and whether anlotinib was combined with chemoradiotherapy or maintenance treatment had no effect on PFS.Conclusion: We found that anlotinib combined with chemoradiotherapy in treating high-grade central nervous system (CNS) tumors can prolong PFS and OS and that it was safe.Keywords
This publication has 32 references indexed in Scilit:
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical TrialJournal of Clinical Oncology, 2013
- Brain Metastasis in Patients With Non–Small-Cell Lung Cancer and Epidermal Growth Factor Receptor MutationsJournal of Clinical Oncology, 2013
- MRI perfusion in determining pseudoprogression in patients with glioblastomaClinical Imaging, 2013
- A prospective phase II single-institution trial of sunitinib for recurrent malignant gliomaJournal of Neuro-Oncology, 2012
- Imaging modalities in high-grade gliomas: Pseudoprogression, recurrence, or necrosis?Journal of Clinical Neuroscience, 2012
- Pseudoprogression and Treatment EffectNeurosurgery Clinics of North America, 2012
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Long-term survival with glioblastoma multiformeBrain, 2007
- Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance SystemJournal of Clinical Oncology, 2004
- Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boostInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1994